Investor relations, scheme partnerships, physician network enquiries, and team opportunities. We'd love to hear from you.
Complete this form to receive the full Aafiya investor deck, including the detailed financial model, clinical validation plan, regulatory strategy, and team bios. For qualified investors and institutional partners only.
Target close Q3 2026. 10–15% dilution. 9–12 months to Series A readiness. Platform substantially built (~R27.1M invested to date).
HPCSA-registered doctors reviewing 15–20 AI-assisted cases/hour at R110/case. Flexible, remote, and fully compliant.
We are building the founding team of 10 across engineering, clinical, and business functions. All roles are South Africa-based.
Location: Cape Town, South Africa.
Registration: Aafiya Med Pty Ltd (SA).
Data Residency: GCP africa-south1 (Johannesburg).
The bridge round is targeting R12–18M in total. Angel and VC commitments from R1–15M are welcome. The platform is substantially built (~R27.1M invested); this round funds clinical validation, SAHPRA engagement, and first scheme partnership.
No. Aafiya is pre-revenue with the platform substantially built. First medical aid revenue targeted at Month 12–18 after bridge close. The bridge round funds the clinical validation, regulatory, and commercial work required to reach first revenue and Series A readiness.
We have designed the platform for SAHPRA compliance from day one and are operating within HPCSA's Booklet 10 telemedicine framework. SAHPRA pre-submission engagement is the immediate next step post-bridge close. SAHPRA Call-Up Notices for AI clinical decision support have not yet been issued — creating a 12–18 month first-mover window for registration.
Aafiya was founded by Dr Bahia Lagardien (CEO, Clinical Lead) and Mogammad Noordien (CTO). The platform has been built with a multidisciplinary team spanning SA healthtech, clinical medicine, AI/ML engineering, and regulatory affairs. Full bios are included in the investor deck.
The medical aid scheme billing model is independently viable at full scale — generating R105M+ net revenue at 480,000 annual consultations without any NHI contribution. NHI capitation is upside, not the base case.
Every AI output is reviewed and signed by an HPCSA-registered physician before reaching the patient. No autonomous AI diagnoses or prescriptions. Red-flag conditions trigger immediate emergency referral (10177). Every action has an immutable audit trail.
Per-consultation economics, revenue ramp to R182M, NHI capitation scenarios, and full cap table.
Five-layer platform design, SA-specific clinical AI, FHIR R4 infrastructure, and security posture.
HPCSA, SAHPRA, POPIA, and NHI Act — how Aafiya meets every regulatory requirement by design.